Skip to content

Keratosis Follicularis Dwarfism Cerebral Atrophy Syndrome C1839910

Published: July 22, 2026Updated: August 20, 2026

A rare genetic syndrome featuring skin bumps, short stature, and brain abnormalities. It affects children and requires multidisciplinary care to address various complications.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
G40.909
ICD-11
8A00.0
Body system
neurologic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Generalized symptoms

(neurologic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Intellectual disability

(neurologic)

Growth retardation

(neurologic)

Ataxia

(neurologic)

Cerebral atrophy

(neurologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Targeted drug therapy with dose adjustment

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
2

Topical Keratolytics for Follicular Keratosis

Application of topical treatments containing urea, alpha-hydroxy acids, or salicylic acid to reduce follicular plugging and improve skin texture.

medication
3

Anticonvulsant Therapy for Seizures

Antiepileptic medications tailored to seizure type and severity to manage seizure activity associated with cerebral atrophy in this syndrome.

medication

Additional treatment options

Developmental Physical Therapy

Specialized therapeutic exercises and interventions addressing motor delays, muscle tone abnormalities, and functional limitations from dwarfism and cerebral atrophy.

physical_therapy

Neuropsychological Support

Cognitive assessment and development of individualized educational and behavioral support plans to address learning difficulties and cognitive impairment.

psychological

Multisystem Surveillance Program

Coordinated monitoring of growth parameters, neurologic status, skin manifestations, and developmental milestones through regular specialist evaluations.

monitoring

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Keratosis Follicularis Dwarfism Cerebral Atrophy Syndrome C1839910?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Medication Comparisons

Compare medications used to treat Keratosis Follicularis Dwarfism Cerebral Atrophy Syndrome C1839910. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy